Business Context and Reporting Period
MiMedx Group, Inc. filed this unaudited Form 10-Q for the three months ended March 31, 2015. The company operates in one segment, Regenerative Biomaterials, developing, manufacturing and marketing human amniotic tissue products and related services for wound care, surgical, sports medicine, ophthalmic and dental markets. Key products include EpiFix and AmnioFix; CollaFix had not yet been commercialized.
Key Financial Metrics
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Net sales | $40.8 million | $19.6 million | Up 108% |
| Gross profit | $35.6 million | $16.6 million | Up 115% |
| Gross margin | 87.4% | 84.8% | Up approximately 260 bps |
| Operating income (loss) | $4.2 million | $(0.9) million | Improved by $5.1 million |
| Net income (loss) | $4.1 million | $(0.9) million | Improved by $5.0 million |
| Basic diluted EPS | $0.04 | $(0.01) | Improved |
| Net cash from operating activities | $4.2 million | $(1.6) million | Improved by $5.8 million |
| Adjusted EBITDA | $8.8 million | $2.0 million | Up $6.8 million |
Operating margin was approximately 10.4%, compared with negative 4.6% in the prior-year quarter. Net margin was approximately 10.0%, compared with negative 4.7%.
At March 31, 2015, cash and cash equivalents were $38.7 million, short-term investments were $6.0 million, and longer-term investments were $2.5 million. Total current assets were $82.3 million versus current liabilities of $18.5 million, producing a current ratio of approximately 4.5. Accounts receivable increased to $31.0 million from $26.7 million at year-end, while inventory declined to $4.2 million from $5.1 million.
The filing does not report material conventional funded debt. Other liabilities included approximately $221,000 of capital lease obligations. Contractual obligations included approximately $5.7 million of operating lease commitments, $400,000 of charitable commitments and $467,000 of meeting-space commitments.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven primarily by higher EpiFix wound-care sales and AmnioFix surgical sales in commercial and government accounts.
- Cost of products sold declined to 12.6% of revenue from 15.2%, reflecting higher direct sales, improved product mix and greater absorption of fixed manufacturing costs.
- Research and development expense increased 31.7% to $1.8 million, primarily from clinical-trial and personnel costs.
- Selling, general and administrative expense increased to $29.3 million from $15.9 million due to expansion of the direct sales organization, higher commissions, share-based compensation, reimbursement support, information technology and patent litigation costs.
- Operating cash flow turned positive, but cash declined by $7.9 million during the quarter because of a $12.3 million share repurchase and $1.3 million of capital expenditures, partly offset by operating cash flow and $1.3 million of option-exercise proceeds.
- The company repurchased 1.36 million shares for approximately $12.3 million before brokerage commissions. Approximately $2.2 million remained under the authorization at March 31; the board increased the authorization to $30.0 million on April 27, 2015.
Guidance, Outlook, Risks and Unusual Items
Management stated that revenue was continuing to increase quarter over quarter and believed existing cash, investments and anticipated operating and financing cash flows would fund operating needs and planned investing activities for the next twelve months. No formal revenue or earnings guidance was provided.
- FDA regulatory risk: The FDA has asserted that the company’s micronized allografts may not qualify for regulation solely as Section 361 HCT/Ps and may require a biologics license. The company initiated a Phase IIB clinical trial in March 2015 and expects to pursue a future biologics license application. Micronized products represented approximately 14% of 2014 revenue. Potential outcomes include labeling or manufacturing restrictions, a requirement for a biologics license, or product recall.
- Litigation: Securities class-action litigation relating to the FDA matter remained in discovery. The company believes it will not materially affect financial condition or results, but the ultimate outcome is uncertain. The Department of Justice declined at that time to intervene in a qui tam matter associated with an OIG subpoena, although private continuation and later government intervention remained possible. A separate shareholder lawsuit filed in February 2015 was voluntarily dismissed on April 22, 2015.
- Patent disputes: The company was pursuing infringement actions against several competitors, while defendants asserted non-infringement and invalidity defenses and challenged certain patents through inter partes review proceedings.
- Tax valuation allowance: The company maintained a full valuation allowance against U.S. deferred tax assets. Management indicated that anticipated profitability could result in releasing some or all of the allowance by year-end 2015; any release would materially affect tax expense in the period recorded.
- Share-based compensation: Q1 stock-based compensation was $3.9 million, up from $2.4 million, and significant additional unrecognized compensation remained.
- Controls: Management concluded that disclosure controls and procedures were effective as of March 31, 2015, with no material change in internal control over financial reporting during the quarter.
Investor Verification Points
- Verify whether revenue growth and gross-margin improvement were sustained after Q1 and how much depended on government and wound-care sales.
- Monitor FDA decisions, clinical-trial progress, biologics-license requirements and any effect on micronized-product sales.
- Assess receivables growth, collection experience and allowances for doubtful accounts and product returns.
- Reconcile operating cash flow with net income, particularly the impact of $3.9 million of stock-based compensation and working-capital changes.
- Track the pace and funding impact of additional share repurchases following the increased $30.0 million authorization.
- Review developments in securities, OIG/qui tam and patent litigation, including potential financial exposure not quantified in the filing.
- Evaluate whether a deferred-tax-asset valuation-allowance release occurs and its effect on reported earnings.